U-93631

0U-93631 is a pharmacological compound that belongs to the class of GABA antagonists. It is primarily used in scientific research to study the role of GABA receptors in the brain and other parts of the body.

History[edit | edit source]

U-93631 was first synthesized in the late 20th century as part of a series of compounds designed to inhibit the action of GABA, a neurotransmitter that plays a key role in the regulation of neuronal excitability. The compound was developed by the pharmaceutical company Upjohn, which later became part of Pfizer.

Pharmacology[edit | edit source]

U-93631 acts as a competitive antagonist at the GABA_A receptor, one of the two classes of receptors that respond to GABA. By binding to the receptor, it prevents GABA from exerting its usual inhibitory effect, leading to increased neuronal activity.

The compound has been used in a variety of research contexts to study the role of GABA_A receptors in processes such as sleep, anxiety, and seizure susceptibility. It has also been used to investigate the potential therapeutic effects of GABA_A receptor modulation in conditions such as epilepsy, insomnia, and anxiety disorders.

Safety and Toxicity[edit | edit source]

Like other GABA antagonists, U-93631 has the potential to cause a range of side effects, including convulsions, anxiety, and insomnia. These effects are due to the compound's ability to increase neuronal activity by blocking the inhibitory action of GABA.